Blood-based comprehensive genomic profiling (CGP)
Blood-based comprehensive genomic profiling (CGP) assay may tackle the significant challenges in NSCLC management, 1) insufficient tumor tissue for molecular testing; 2) complexity of genotype related treatment decision, see bTMB and BFAST [102P]
Clinical efficacy of atezolizumab
Clinical efficacy of atezolizumab in PD-L1 selected subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: results from the randomized OAK trial [1296O], Shirish Gadgeel, et al